Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

NRF2 inhibitor

DRUG CLASS:

NRF2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

HER-2 positive	Ovarian Cancer	HER-2 positive	Ovarian Cancer	trastuzumab + brusatol Sensitive: D – Preclinical trastuzumab + brusatol Sensitive : D	trastuzumab + brusatol Sensitive: D – Preclinical trastuzumab + brusatol Sensitive : D
HER-2 overexpression	Ovarian Cancer	HER-2 overexpression	Ovarian Cancer	brusatol Sensitive: D – Preclinical brusatol Sensitive : D	brusatol Sensitive: D – Preclinical brusatol Sensitive : D
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	brusatol Sensitive: D – Preclinical brusatol Sensitive : D	brusatol Sensitive: D – Preclinical brusatol Sensitive : D
MYC overexpression	Lymphoma	MYC overexpression	Lymphoma	brusatol Sensitive: D – Preclinical brusatol Sensitive : D	brusatol Sensitive: D – Preclinical brusatol Sensitive : D
KEAP1 expression	Chronic Lymphocytic Leukemia	KEAP1 expression	Chronic Lymphocytic Leukemia	ibrutinib + brusatol Sensitive: D – Preclinical ibrutinib + brusatol Sensitive : D	ibrutinib + brusatol Sensitive: D – Preclinical ibrutinib + brusatol Sensitive : D
KEAP1 expression	Chronic Lymphocytic Leukemia	KEAP1 expression	Chronic Lymphocytic Leukemia	brusatol Sensitive: D – Preclinical brusatol Sensitive : D	brusatol Sensitive: D – Preclinical brusatol Sensitive : D
NFE2L2 expression	Chronic Lymphocytic Leukemia	NFE2L2 expression	Chronic Lymphocytic Leukemia	ibrutinib + brusatol Sensitive: D – Preclinical ibrutinib + brusatol Sensitive : D	ibrutinib + brusatol Sensitive: D – Preclinical ibrutinib + brusatol Sensitive : D
NFE2L2 expression	Chronic Lymphocytic Leukemia	NFE2L2 expression	Chronic Lymphocytic Leukemia	brusatol Sensitive: D – Preclinical brusatol Sensitive : D	brusatol Sensitive: D – Preclinical brusatol Sensitive : D